ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
34 announcements
GSK Pharma's postal ballot approved Ms. Natland as NED and Mr. Akshikar's MD re-appointment. Both resolutions cleared with over 99% shareholder support.
GlaxoSmithKline Pharmaceuticals issued a corrigendum for its August 3, 2026, postal ballot notice, correcting a typographical error in a reported salary figure.
GlaxoSmithKline Pharmaceuticals clarified that recent trading volume increases are purely market-driven. The company confirmed all material disclosures have been made according to SEBI regulations.
GlaxoSmithKline Pharmaceuticals received an income tax refund intimation of Rs 4.99 Crore for the assessment year 2025-2026.
GlaxoSmithKline Pharmaceuticals has issued a Postal Ballot notice for shareholder approval. The resolutions involve appointing Karine J F Natland and re-appointing Bhushan Akshikar as Managing Director.
GlaxoSmithKline Pharmaceuticals received a ₹52.00 Crore tax refund plus ₹42.09 Crore interest income following a favorable CIT-Appeal order for assessment year 1984-85.
GSK India delivered resilient FY26 results with double-digit EBITDA and PAT growth, despite muted 2% revenue growth due to significant supply disruptions from a CMO fire and vaccine shipment delays.
GSK reported muted 2% revenue growth due to supply chain disruptions at a key CMO, but delivered record-high EBITDA margins of 35% through cost optimization and a shift toward high-margin specialty products.
GSK Pharmaceuticals reported the resignation of Director Subesh Williams and the re-appointment of Executive Director Bhushan Akshikar effective December 1, 2026.
GSK India reported Q1 FY27 financial results with revenue at INR 924 crore and PAT at INR 253 crore. The company highlights growth across key therapeutic portfolios.
GSK India delivered strong Q1 FY27 standalone performance with revenue growing 15% and PAT up 24%, driven by portfolio transformation and core brand leadership.
GlaxoSmithKline Pharmaceuticals Ltd reported revenue from operations of ₹938.4 Cr (+16.5% YoY) and net profit of ₹237.2 Cr (+15.7% YoY) for Q1 FY27.
GlaxoSmithKline Pharmaceuticals Ltd scheduled a board meeting for August 3, 2026. The board will consider and approve un-audited financial results for Q1 ended June 30, 2026.
GLAXOSMITHKLINE PHARMACEUTICALS disclosed its shareholding pattern as per regulatory requirements. No monetary or transactional event was announced.
GlaxoSmithKline Pharmaceuticals received a Demand Notice from NPPA demanding Rs.3,54,12,025. The company says the demand has no financial impact and will appeal.
GlaxoSmithKline Pharmaceuticals has issued notice for its 101st AGM scheduled for June 30, 2026. Shareholders will consider a Rs. 57 per share dividend declaration.
GlaxoSmithKline Pharmaceuticals submitted its Business Responsibility and Sustainability Report for FY 2025-26. The report details the company's ESG performance, safety standards, and community initiatives.
GlaxoSmithKline Pharmaceuticals submitted its Annual Report for FY2025-26. The report outlines its strategic focus on oncology, specialty medicines, and digital transformation for future growth.
Dr. Simrat Sohal resigned as Compliance Officer of GlaxoSmithKline Pharmaceuticals, effective August 5, 2026. This transition requires the company to appoint a successor for regulatory compliance.
GlaxoSmithKline Pharmaceuticals filed its Annual Secretarial Compliance Report for FY2026 showing full regulatory adherence. No fines or observations were reported by the practicing company secretary.
GSK Pharma Q4 FY26 earnings call highlighting 2% revenue growth, 34% EBITDA margins, and a shift toward an innovation-led specialty portfolio.
GSK India delivered double-digit EBITDA and PAT growth for FY26 despite supply disruptions. Performance was bolstered by a transition toward high-margin specialty oncology and adult vaccines, compensating for a muted general medicine segment.
GlaxoSmithKline Pharmaceuticals recommended a final dividend of ₹57 per equity share for 2026. The record date is May 29, 2026, pending shareholder approval.
GSK India reported full-year revenue of ₹3790 Crore and PAT of ₹1012 Crore. The board recommended a final dividend of ₹57 per equity share.
GSK India delivered a strong FY26 with 34.3% EBITDA margins and its first-ever PAT exceeding ₹1000 cr, driven by portfolio shifts toward high-growth Specialty and Innovative segments.
GlaxoSmithKline Pharmaceuticals Ltd reported revenue from operations of ₹995.3 Cr (+2.1% YoY) and net profit of ₹277.9 Cr (+5.7% YoY) for Q4 FY26.
GSK Pharmaceuticals reported a consolidated net profit of ₹1,035.98 Crore for FY2026. The board also recommended a final dividend of Rs. 57 per share.
GlaxoSmithKline Pharmaceuticals Limited has scheduled a board meeting on May 13, 2026. The board will consider audited standalone and consolidated financial results for the year ended March 31, 2026, and recommend a final dividend. The trading window remains closed until May 16, 2026.
GlaxoSmithKline Pharmaceuticals Limited has scheduled a Board Meeting on May 13, 2026. The directors will consider and approve the audited standalone and consolidated financial results for the year ended March 31, 2026. The board will also consider recommending a dividend on equity shares for the period.
GlaxoSmithKline Pharmaceuticals Ltd has authorized specific personnel, including the Managing Director and CFO, to determine the materiality of events for disclosure under SEBI Regulations. This administrative update ensures compliance with Regulation 30(5) regarding timely communication to stock exchanges.